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Efficacy of protected renal artery primary stenting
in the solitary functioning kidney
Chris Klonaris, MD, Athanasios Katsargyris, MD, Andreas Alexandrou, MD, Chris Tsigris, MD,
Athanasios Giannopoulos, MD, and Elias Bastounis, MD, Athens, Greece
Background: Significant renal artery stenosis (RAS) in a solitary functioning kidney (SFK) represents one of the most
acceptable indications for renal revascularization. Percutaneous transluminal renal artery stenting (PTRAS) is increas-
ingly being used as a first line treatment for renal revascularization, associated with renal function improvement or
stabilization in the majority of the patients with solitary kidneys, but also with deterioration in up to 38% of the cases.
Atheroembolism during PTRAS has been postulated as a potential cause for this acute renal function worsening. The aim
of this study was to report on the feasibility, safety, and early outcomes of PTRAS in a series of patients with SFK using
distal embolic protection (DEP).
Methods: All PTRAS procedures in SFKs performed under DEP between June 2002 and September 2007 were reviewed.
Renal function, blood pressure, and the number of anti-hypertensive medications were assessed pre- and post-
intervention. Renal function improvement and deterioration were defined as a 20% increase and decrease in serum
creatinine, respectively, compared with preoperative values. Primary and primary assisted patency rates were also
calculated. Statistical differences between values before and after intervention were determined by the Student t test and
statistical significance was taken at P < .05.
Results: Protected PTRAS was performed in 14 patients with a SFK (9 men, 6 women, mean age 65.6  6.8 years). All
patients were hypertensive and had varying degrees of azotemia. Mean pre-intervention stenosis degree was 86.8% 
7.8%. Immediate technical success was obtained in 100% of the patients. Renal function was cured (7.1%), improved
(50%), or stabilized (42.9%) in all 14 (100%) patients after the procedure and no deterioration was noticed in any patient
at 6-month follow-up. Pre- and postintervention serum creatinine levels were 3.01  1.15 mg/dL and 2.16  0.68
mg/dL, respectively, (P  .02). Hypertension was improved in 6 (42.9%) patients and stabilized in the remaining 8
(57.1%). Primary patency was 100% and 90% at 1 and 3 years, respectively, while primary assisted patency remained 100%
for the whole follow-up period (mean, 31.8  19.4 months).
Conclusion: These findings suggest that in patients with a SFK, protected PTRAS represents a safe and effective treatment
for halting the progression of renal dysfunction to renal loss and warrants further investigation. (J Vasc Surg 2008;48:
1414-22.)Renovascular disease is considered to be responsible for
approximately 12% of end-stage renal disease (ESRD) cases.1
The progressive nature of renal artery stenosis (RAS) and its
adverse effects in the cardiovascular system, renal function,
and survival have been well established.2,3 The severity of
RAS pattern directly affects survival; 2-year dialysis-free
survival has been reported to be 97.3% for patients with
unilateral RAS, 82.4% for patients with bilateral RAS but
only 44.7% in patients with renovascular disease in a solitary
functioning kidney.2 Over the last decades, RAS has been
recognized as a potentially correctable cause of hyperten-
sion and renal insufficiency4 and revascularization with
endovascular techniques is currently advocated by many
clinicians in an attempt to preserve renal function especially
in individuals with solitary functioning kidneys (SFKs).
To date, only a small number of studies have evaluated
the efficacy of percutaneous transluminal renal artery stent-
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1414ing (PTRAS) in patients with SFKs.5-10 Although PTRAS
was shown to improve or stabilize renal function in the
majority of the patients, it was also associated with renal
function deterioration in 13-38% of the cases. Based on the
hypothesis that this phenomenon may be partly or totally
due to distal atheroembolization during the procedure, we
investigated the use of distal embolic protection (DEP)
devices in patients undergoing primary stenting of the renal
artery for solitary kidney salvage. To our knowledge, this is
the first series in the literature reporting the outcomes of
protected PTRAS in the SFK.
METHODS
Patients. The medical records of all patients with RAS
in a SFK that were treated with PTRAS under distal em-
bolic protection during the period from June 2002 to
September 2007 were retrospectively analyzed for this
study. Materials reviewed included records from the out-
patient clinic, noninvasive vascular laboratory, and hospital
and endovascular operating suites that provided informa-
tion about patients’ demographics, indications for inter-
vention, procedural details and complications, postopera-
tive course, and renal artery patency during follow-up.
Primary or referring physicians were also contacted for
additional information and data.
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ultrasonography scan and digital subtraction angiography
(DSA). All patients were admitted to our department the
day before the procedure for overnight intravenous hydra-
tion.
Indications for treatment included a hemodynamically
significant RAS (60% as measured at DSA) in a SFK with
length 80 mm. All patients provided informed consent
before the procedure.
Procedure. All interventions were performed under
local anesthesia in the endovascular suite. A retrograde
femoral approach was utilized in 13 cases, while in 1 patient
with acute aorto-renal angle the procedure was performed
through right brachial artery catheterization. A bolus of
5000 IU of intravenous heparin was administered routinely
once access was obtained. Selective cannulation of the renal
artery was achieved with a 7F angled guiding catheter
(Renal Double Curve). The lesion to be treated was not
crossed with the guide catheter. Subsequently, the distal
protection filter device (EX/EZ Filterwire, Boston Scien-
tific Corporation, Natick, Mass; n  10, RX Accunet,
Abbott Vascular, Abbott Park, Ill; n 4) was advanced and
deployed at the distal main renal artery. Complete filter
apposition to the vessel wall was checked with fluoroscopy
in at least two oblique views looking for contrast floating
around the filter. Afterwards, balloon expandable stents
were positioned and deployed primarily without predila-
tion, with a slight protrusion of 1-2 mm into the aortic
lumen, while also covering the whole length of the lesion to
be treated. Predilation was avoided in order to minimize
debris dislodgement before covering the lesion with the
stent. Sizing of the stents was based on the diameter of
the distal healthy main renal artery. Six stents (42.9%)
were inflated up to 5mm, while the remaining 8 (57.1%) up
to 6 mm. Regarding stent length, we used the shorter stent
that was adequate to cover the whole stenosed segment.
After stent deployment and arteriographic confirma-
tion of satisfactory stent placement, the filter was recap-
tured. The particles collected in the filter were sent for
pathologic analysis. Hemostasis was achieved with local
pressure alone at the puncture site. The iodinated contrast
(Ultravist-300, Schering, Germany, concentration: 300
mgI/mL) was diluted by half during the procedure; its
amount was closely monitored and never exceeded 50 mL.
After the procedure, double antiplatelet treatment with
aspirin (100 mg/day) and clopidogrel (75 mg/day) was
administered for 1 month, and then monotherapy with
aspirin (100 mg/day) was continued long term.
Patients remained in the hospital for 48 hours to mon-
itor their serum creatinine and adjust their antihypertensive
drugs.
Follow-up imaging studies with renal artery color du-
plex scanning were scheduled at 3 and 6 months postinter-
vention and then biannually. DSA was performed only
when significant restenosis was suspected due to positive
clinical and ultrasound scan findings and reintervention was
considered. Serum creatinine levels were measured 1 day
before and after the procedure and at 1, 3, and 6 months,with biannual measurements thereafter by the primary-
referring physicians of the patients.
Definitions, outcome measures, and statistical
analysis. Lesions were considered ostial if they involved
the first 5 mm of the main renal artery.11 The arterial
stenosis degree was calculated at duplex ultrasonography
scan (renal artery peak systolic velocity [PSV] 1.8 m/
second and presence of postenotic turbulence for deter-
mining a hemodynamically significant stenosis)12 and was
confirmed at angiogram by comparing the narrowest lu-
men of the renal artery with the nearest normal distal lumen
unaffected by post-stenotic dilatation.
Immediate technical success was defined as safely cross-
ing and stenting the stenosis with no significant procedural
complications, a residual stenosis 30% of the reference
diameter as measured on angiogram and no flow-limiting
intimal dissection.13 Inability to place the filter successfully
at the correct position and/or to achieve complete apposi-
tion with the vessel wall to protect the renal parenchyma
throughout the procedure was considered to be device
failure.
Blood pressure (BP) changes were assessed on the basis
of the criteria established by the cooperative study on
renovascular hypertension.14 A diastolic pressure of 90 mm
Hg or less without anti-hypertensive medication was con-
sidered cured. A decrease in diastolic pressure of 15% or
more without any change in the number of anti-
hypertensive medications was considered an improvement.
Failure was considered an increase of 15% or more in the
diastolic pressure after stenting. The rest of the cases were
classified as stable.
Moderate renal insufficiency was defined as baseline
serum creatinine 1.5 and 2.0 mg/dL, while creatinine
values2.0 mg/dL were categorized as severe renal insuf-
ficiency.11,15
Renal function improvement was defined as a decrease
of 20% or more in the serum creatinine level post-
intervention (1 and 6 months) compared to the preopera-
tive baseline level. An increase of 20% ormore from baseline
level was classified as deterioration in renal function and
creatinine values within 20% of baseline were considered to
be unchanged.5,8 Renal function cure was defined as serum
creatinine 1.4 mg/dL after the procedure.
Restenosis was defined as a decrease in renal artery
diameter 50% detected by duplex ultrasonography scan
(renal artery PSV 2.2 m/second) and confirmed at DSA
during follow-up. Primary patency was defined as patent
stents (stenosis 50%) detected at duplex ultrasound scan
during follow-up without any further intervention, while
primary assisted patency was defined as patent stents (ste-
nosis 50%) after successful additional percutaneous pro-
cedures.7
Statistical analysis was done with SPSS 10.0 software
(SPSS Inc, Chicago, Ill). Continuous data are presented as
mean  standard deviation (SD) and categorical data as
percentages. Statistical differences between groups were
determined by the Student t test. Statistical significance was
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follow-up was reported by Kaplan-Meier analysis.
RESULTS
From June 2002 to September 2007, 14 patients
(9 men; mean age 65.6  6.8 years) who were diagnosed
with RAS to a SFK were treated with percutaneous primary
stenting under filter protection.
Patients’ demographics are shown in Table I. All pa-
tients suffered from hypertension and were on anti-
hypertensivemedications (2-4 drugs). Seven (50%) patients
had an occluded contralateral renal artery, 5 (35.7%) had
had a previous nephrectomy due to trauma or malignancy
and 2 (14.3%) had a congenital solitary kidney.
All had varying degrees of azotemia (mean serum cre-
atinine 3.01  1.15 mg/dL); 3 (21.4%) patients had
moderate renal insufficiency, 10 (71.4%) had severe renal
dysfunction and 1 (7.1%) presented with acute solitary
renal artery occlusion (serum creatinine: 6.1 mg/dL).
None of the patients was on hemodialysis before revascu-
larization.
The stenosis was located at the ostium of the solitary
renal artery in all 14 (100%) cases. Mean degree of stenosis
was 86.8% 7.8% (range, 70%-100%). Mean lesion length
was 14.2  2.9 mm (range, 9-19 mm). The normal diam-
eter of the artery was estimated at 5 mm in 6 cases and 6
mm in 8 cases. Eleven (78.6%) patients had diffuse athero-
sclerosis of the abdominal aorta. One patient also had a 5.4
cm abdominal aortic aneurysm (AAA) that was treated with
a two-stage procedure consisted of initial PTRAS followed
by endovascular aneurysm repair (EVAR) 2 weeks later. A
second patient suffered from a 6.4 cm type III thoracoab-
dominal aortic aneurysm (TAAA) and a 4.2 cm infrarenal
AAA; the TAAA was treated with endovascular techniques
1 month after renal stenting, while the AAA is still being
under surveillance.
All 14 lesions were treated with primary stenting. Four-
teen balloon-expandable stents of different types according
to operator choice (Corinthian, n  2, Cordis Endovascu-
lar, Warren, NJ; Herculink, n 7, Abbott Vascular, Abbott
Park, Ill; Express, n  5; Boston Scientific Corporation,
Natick, Mass) were advanced and placed at the appropriate
Table I. Patient demographics (n  14)
Gender (M:F)
Age (years)
Risk factors (n  14)
Smoking history
Coronary artery disease
Diabetes mellitus
Peripheral arterial disease
Blood pressure (mm Hg)*
Systolic
Diastolic
Number of antihypertensive drugs*
Serum creatinine level (pre-procedure)*
*Expressed as mean  standard deviation.position in main renal artery under filter protection. All 14patients required only one stent for complete covering of
their lesion. Immediate technical success was obtained for
all 14 arteries (100%) with good stent deployment, no
significant residual stenosis, and complete lesion coverage.
All lesions were easily crossed with the protection filters
while there were no difficulties in removing the protection
filters. In 12 out of 14 cases, complete apposition of the filter
to the vessel wall was achieved, while there were two device
failures,where therewas contrast floating around the filter due
to increased main renal artery diameter (Fig 1). The mean
time in situ for filters was 4.6 1.12 minutes. One patient
developed an arterial spasm at the site of the protection
filter, which responded well to local vasodilation therapy.
No dissection of the vessel artery due to a protection filter
was observed in these 14 cases.
Macroscopic visible debris collected in the filter was
found in nine cases (64.3%); while microscopic evaluation
detected particles in 11 of 14 filters (78.6%). The remainder
of the baskets were either empty or contained insufficient
material to survive processing. Qualitative analysis with
light microscopy revealed that the particles consisted of
atheromatous plaques, cholesterol crystals, necrotic cores,
fibrin, thrombi, platelets, and macrophage foam cells.
Follow-up. The mean follow-up period was 31.8 
19.4 months (range, 6-67 months). In all cases, follow-up
was beyond the period for development of clinical manifes-
Fig 1. A, Preoperative DSA demonstrating a significant left renal
artery ostial stenosis in a solitary functioning kidney.B,Angiogram
after stent placement showing successful revascularization without
residual stenosis. Note the contrast floating around the filter due to
incomplete apposition to the vessel wall (arrow).
9:5 (64.3:35.7%)
65.6  6.8 (range, 48-72)
10 (71.4%)
9 (64.3%)
5 (35.7%)
8 (57.2%)
171.8  10.7 (range, 162-205)
92.1  4.3 (range, 91-110)
2.8  0.6 (range, 2-4)
3.01  1.15 mg/dL (range, 1.6-6.1 mg/dL)tations of atheroembolism.16 Two patients died from myo-
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months after the procedure.One patient was lost to follow-up
after 12 months.
Renal function was cured (7.1%), improved (50%), or
stabilized (42.9%) in all 14 (100%) patients after the pro-
cedure and no deterioration was noticed in any patient until
the 6-month follow-up. Additionally, there was a statisti-
cally significant reduction in the mean serum creatinine
level from 3.01  1.15 mg/dL preprocedurally to 2.16 
0.68 mg/dL 1-month post intervention that was sustained
(2.16  0.59 mg/dL) at 6-month follow-up. Exclusion
from the analysis of the patient with the outlier serum
creatinine value of 6.1 mg/dL that is very likely to repre-
sent an acute on chronic renal failure situation and not a
steady state chronic creatinine level, revealed a less marked,
but still statistically significant decrease in the mean serum
creatinine level (2.78  0.76 mg/dL preprocedurally to
2.24  0.65 mg/dL 1-month postintervention and 2.2 
0.6 mg/dL 6 months after the procedure, P  .05). No
patient required dialysis during the long-term follow-up
(mean 31.8  19.4 months).
Regarding the effects of the procedure on hyperten-
sion, there was a statistically significant reduction in both
systolic (P  .017) and diastolic BP (P  .008) and in the
number of anti-hypertensive drugs (P  .002) after
PTRAS. In addition, hypertension was improved in 6
(42.9%) patients and remained unchanged in 8 (57.1%)
after the procedure (Tables II and III).
No 30-day mortality was observed in this series. One
(7%) patient developed a minor access-site hematoma that
was treated nonoperatively. In-stent restenosis was de-
tected in 2 patients in this series. The first one was detected
at 15 months after the procedure and was successfully
treated with angioplasty. At 30 months, a new restenosis
was found at the distal edge of the previously placed stent
and a 6 mm  22 mm balloon-expandable covered stent
was placed (Advanta V12, Atrium Medical, Hudson, NH)
without residual stenosis. Distal embolic protection was
Table II. Statistical significance between baseline and pos
Variable B
Systolic blood pressure (mm Hg)* 171.8  1
Diastolic blood pressure (mm Hg)* 92.1  4
Number of anti-hypertensive medications* 2.8  0
Serum creatinine level (mg/dL)* 3.01  1
*Expressed as mean  standard deviation (range).
Table III. Clinical outcome after stenting (n  14)
Cured Improved Stabilized Deteriorated
Hypertension 0 6 (42.9%) 8 (57.1%) 0
Creatinine 1 (7.2%) 7 (50%) 6 (42.8%) 0
Antihypertensive
drug number 0 9 (64.3%) 5 (35.7%) 0not used in any of these two procedures due to technicaldifficulties owing to the protrusion of the proximal edge of
the renal stent in the aortic lumen. The second patient
suffered an in-stent restenosis at 48 months and was treated
successfully with stenting under filter protection. Until the
most recent available follow-up, both these patients were
doing well without any signs of recurrent stenosis. Kaplan-
Meier analysis of primary patency is shown in Fig 2. Primary
patency was 100% and 90% at 1 and 3 years, respectively,
while primary assisted patency remained 100% for the
whole follow-up period (mean, 31.8  19.4 months).
DISCUSSION
Renal artery stenosis in the SFK represents the most
severe pattern of renovascular disease; patients with a sig-
nificant RAS to a SFK are at a markedly increased risk of
renal loss. In this patient population, the probability of total
renal artery occlusion is high, and if this occurs, the out-
come is abrupt loss of functioning renal mass, with resulting
renal failure.4,17 Additionally, ischemic nephropathy or
flash pulmonary edema almost always occurs in the pres-
ence of bilateral RAS or disease in a SFK.4Moreover, 2-year
dialysis-free survival has been reported to be only 44.7% in
case of RAS in a SFK, in contrast to 97.3% for patients with
unilateral disease.2 Thus, revascularization of the SFK is
advocated in an effort to halt the progression of renal
dysfunction and most importantly to prevent kidney loss.
rventional values
e Post-interventional P
162-205) 150.4  25.9 (120-196) .017
1-110) 80.9  14.6 (68-107) .008
-4) 1.8  1.1 (1-4) .002
1.6-6.1) 2.16  0.68 (1.2-3.9) .02
Fig 2. Kaplan-Meier analysis of primary patency after protected
renal artery stenting in the solitary functioning kidney.t-inte
aselin
0.7 (
.3 (9
.6 (2
.15 (Indeed, RAS in a SFK is among factors that may predict a
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interventional treatment of a RAS in a SFK owing to the
dismal prognosis of these patients is well reflected in the
latest American College of Cardiology/American Heart
Association (ACC/AHA) practice guidelines; RAS to a
single functioning kidney in patients with progressive
chronic kidney disease represents the indication with the
highest level of evidence (level B) for percutaneous revas-
cularization as an attempt to preserve renal function.19
Renal artery revascularization may also be useful in
hypertension control. Current evidence supports that pa-
tients with severe atherosclerotic RAS and accelerated,
resistant, or malignant hypertension may expect to receive
some clinical benefit after renal revascularization.19 Espe-
cially for patients with a SFK, RAS treatment may also allow
for long-term administration of otherwise contraindicated
angiotensin antagonist medications with additional bene-
fits in cardiovascular risk reduction.19
Endovascular therapy including percutaneous translu-
minal renal angioplasty (PTRA) and stenting has emerged
as an advantageous treatment strategy for renovascular
disease during the last 2 decades. Stent placement in the
renal artery ostium significantly improves primary and sec-
ondary patency rates compared with PTRA alone as previ-
ously outlined by Blum et al11 and other authors.11,20-23
The superiority of stenting has been also confirmed in a
recent randomized trial,24 where stent implantation in
ostial atherosclerotic RAS was associated with a higher
primary success rate (88% vs 57%) and a lower restenosis
rate (14% vs 48%), in comparison with PTRA.
However, despite the high technical success rate, long-
term patency and low complication rates, PTRAS often fails
to improve or stabilize renal function. Indeed, renal func-
tion deterioration may occur in a significant proportion of
patients after renal percutaneous revascularization,25,26
limiting, thus, the benefits of the procedure. Several expla-
nations have been proposed for this phenomenon includ-
ing contrast media-induced nephrotoxicity, unsuspected
irreversibility of pre-existing renal parenchyma damage,
progression of atherosclerosis, reperfusion injury, and most
importantly, atheroembolism during angioplasty and stent-
ing.27-29
Atheroemboli to the kidney, beyond mechanical occlu-
sion of smaller vessels distal to the stenosis is also known to
cause local vascular inflammation resulting in substantial
renal parenchyma damage. It has been suggested that athero-
genic lipoproteins contained in released atheroemboli along
with circulating cytokines may induce endothelial- and
epithelial-cell dysfunction and vascular damage distal to the
stenosis and infiltrate the mesangium and blood vessels.30
This promotes growth factor secretions that result in glo-
merular and vascular remodeling and proliferation of extra-
cellular matrix.27 Prognosis of atheroembolic renal disease
(AERD) is poor; up to 40-50% of the patients will require
dialysis, while complete recovery of renal function is ex-
pected to only one-fifth to one-third of the patients.31,32
Unfortunately, several factors such as the uncertain inci-
dence, insidious and nonspecific clinical manifestations,and difficulty for definite diagnosis contribute to under-
estimation or misdiagnosis of AERD after renal artery
interventions in clinical practice.
Nevertheless, there is increasing evidence that PTRAS
produce atheroembolic debris that can strongly affect renal
function. Ex vivo manipulation of the atheromatous renal
artery ostium has been shown to release large numbers of
embolic particles during angioplasty and stenting.28 Addi-
tionally, a recent in vivo study demonstrated that on aver-
age 2000 atheroembolic particles are liberated during renal
artery angioplasty and stenting, while the increasing parti-
cle count was found to be significantly and independently
associated with the extent of short-term renal function
impairment post intervention.33 Moreover, Al-Hamali
et al34 has demonstrated that Doppler scan embolic signals
can be recorded over the femoral arteries for 2 hours after
renal angioplasty, implying that there is significant debris
release during renal angioplasty. Finally, Kimura et al35
injected different numbers of acryl bead microspheres to
mimic atheroembolic disease in rats; interestingly, the out-
comes in terms of renal dysfunction were dependent on the
initial dose of microspheres and only the largest dose re-
sulted in renal function decline indicating that there may be
a dose-effect relationship in AERD.
According to the aforementioned considerations, it was
speculated that reduction or even elimination of atheroem-
bolic debris generated during the procedure could poten-
tially improve the results of endoluminal renal artery inter-
ventions. Beyond the “no touch” technique proposed by
Feldman et al,36 few investigators published their experi-
ence with renal angioplasty and stenting under DEP29,37-39
particularly in patients with unilateral disease. These studies
demonstrated the feasibility and safety of the procedure and
revealed the beneficial role of DEP, documenting zero or
very low rates of renal function impairment (0-3%) after
PTRAS.
Based on these limited but promising results derived
particularly from patients with unilateral RAS, we were
prompted to investigate the use of DEP in individuals with
a SFK, who probably represent the most vulnerable patient
population for developing renal failure after an atheroem-
bolic event during PTRAS. In this series, all 14 ostial
atherosclerotic lesions were primarily stented under DEP
with favorable results. Renal function was cured or im-
proved in 57.2% and stabilized in the remaining 42.8%.
These results are in agreement with the aforementioned
series using DEP in patients unilateral disease.38,40
To date, only a small number of studies5-10 document-
ing percutaneous revascularization in the SFK exist in the
literature, all without the use of DEP (Table IV). In these
series, renal function was improved in 21-62% and stabi-
lized in 19-55%, but it was also acutely deteriorated in
13-38% of the patients after percutaneous revasculariza-
tion. Compared with these previously published series, our
results represent a marked improvement in terms of short-
term renal function response rates after PTRAS, since there
was no renal function worsening in any of our patients. This
is of great significance especially in light of already pub-
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sponse following PTRAS is a robust predictor of subse-
quentmorbidity andmortality.38,41,42We hypothesize that
this is probably due to the reduction/elimination of athe-
roembolization during the procedure owing mainly to the
use of DEP devices. To our knowledge, no other series
exists in the literature focusing on the efficacy of DEP
during PTRAS in the SFK.
In this series, all RAS were directly stented success-
fully without predilation, which may have also contrib-
uted in the zero rate of renal function deterioration
succeeded in our patients. Indeed, covering the lesion
with a stent before angioplasty may reduce the possibility
of distal embolization, since the potentially embolic
material is trapped between the stent and the arterial
wall. Prospective randomized studies are necessary in
order to definitely clarify this issue; however, since such
evidence is not currently available, the decision regard-
ing predilation of a RAS is based mainly on arbitrary data
and physicians’ personal opinion.
As already noticed, additional mechanisms other
than atheroembolism may also contribute to renal func-
tion deterioration after PTRAS including progression of
atherosclerosis, reperfusion injury, and contrast-induced
nephrotoxicity.27 However, our findings indicate that
atheroembolism may probably be the most significant
Table IV. Results of renal artery stenting in the solitary fu
Author
No. of
cases
Technical
success (%) Complications (%)
Effe
renal f
Shannon10 21 100 28.6 43% Impr
29% Stab
29% Dete
Bush5 27 93 22 46% Impr
28% Stab
25% Dete
Cioni7 16 100 0 62% Impr
19% Stab
19% Dete
Chatziioannou6 26 100 8 35% Impr
27% Stab
38% Dete
Sahin8 15 100 26.8 60% Impr
27% Stab
13% Dete
Tan9 75 100 25 21% Impr
55% Stab
21% Dete
Present study 14 100 7.2 7.1% Cur
50% Impr
42.9% Sta
0% Deter
1Follow up duration is expressed in months.
2Primary patency at 9 months.
3Primary patency at 24 months.
4Primary patency at 12 months.
5Primary patency at 36 months.factor affecting renal function after PTRAS, since elimi-nation of distal emboli with DEP utilization resulted in
prevention of renal function worsening in all patients.
Despite the good overall results in this patient cohort
with the use of DEP, it should be noticed that embolic
protection filters still have limitations that can potentially
jeopardize the success of percutaneous renal artery inter-
ventions. Filter placement and deployment represent an
additional step to the procedure and carry a small, but
existent risk of complications such as arterial dissection,
spasm, or intimal damage. Additionally, particles smaller
than 100 m, which is the average filter pore size of the
majority of commercially available filters, are not captured
and can occlude the afferent arteriole and/or glomeru-
lus.28 Moreover, in several cases, renal artery shows early
branching with a short main renal artery; this can make it
difficult or impossible to anchor the filter distally enough in
order to secure access and have adequate stability to ad-
vance the stent and at the same time protect the whole
kidney rather than only a portion supplied by one renal
artery division. In such cases, the use of eccentric filters with
a beveled ring (eg, EZ/EX Filterwire, Boston Scientific
Corporation) may be preferential (Fig 3). In addition, the
“short renal artery phenomenon”may also compromise the
ability to get the stiffer-working portion of the wire well
seeded into themain renal artery across the target lesion. Of
note, during the time frame of the study, 2 patients with
ning kidney
on
Effect on
hypertension
Mean follow-up
(range)1
Primary
patency (%)
ent
on
tion
15 1002
ent
on
tion
20.7  17 (0.3-60.2)
ent
on
tion
88% Improvement
13% Stabilization
0% Deterioration
21 (6-36) 753
ent
on
tion
3
ent
on
tion
6.7% Cure
26.6% Improvement
66.7% Stabilization
0% Deterioration
(12-60) 69.23
ent
on
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22% Improvement
70% Stabilization
7% Deterioration
12
ent
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on
42.9% Improvement
57.1% Stabilization
0% Deterioration
31.8  19.4 (6-67) 1004
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ilizati
riora
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riora
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riora
e
ovem
biliza
ioratiSFK were judged unfit for filter placement due to early
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out DEP, thus, being excluded from the present series.
Finally, some filters are designed for vessel diameters up to
5.5 mm, which in some cases may be slightly smaller than
the main renal artery that ranges from 5.5 to 7 mm, thus
resulting in incomplete apposition of the filter to the vessel
wall and debris floating around the filter loop. The latter
did indeed occur in 2 of our patients without, however, any
apparent clinical sign of distal embolization. In any case,
however, even “partial protection” is probably preferable to
“no protection”.35
Currently, all embolic protection devices have been
designed and approved for use in coronary saphenous vein
grafts and carotid artery stenting, while their use in the
renal artery has been extended “off label”. Appropriate
refinements in filter engineering with filters designed spe-
cifically for renal artery anatomy are necessary before filter
embolic protection technology can be used to its full ad-
vantage in renal percutaneous revascularization proce-
dures. More specifically, in comparison with the currently
available filter devices, renal artery filters should ideally
have: (1) Lower profile and better flexibility, pushability,
andmaneuverability in order to deal with the perpendicular
access needed due to the acute aortorenal angle. (2) In-
creased guidewire strength so as to minimize the need for
very distal anchoring and facilitate stent advancement over
the aortorenal junction. (3) Reduced landing zone require-
ments so that it can be used even in cases of early renal
artery bifurcation. (4) Shorter length of the floppy portion
of the wire. (5) Availability of larger ring diameters up to
7mm in order to provide complete vessel wall apposition in
Fig 3. Drawing shows the use of an eccentric filter with a beveled
ring in order to provide complete renal protection in cases of short
main renal artery; the tip of the filter is anchored distally in one
renal artery branch, while the proximal beveled part of the basket
remains in the main renal artery protecting both renal artery
divisions.all cases. (6) Different mesh structure to capture particlessmaller than 100 m, which can occlude the afferent arte-
riole and/or glomerulus.28
Blood pressure improvement was observed in 42.9% of
our patients. Review of other series reveals a great variation
in BP response to percutaneous revascularization of the
SFK ranging from 22-88%.7,9 Several factors may be re-
sponsible for this variance, including different follow-up
periods, perhaps too short in some studies to allow for BP
improvement detection, coexisting severe essential hyper-
tension in some patient cohorts, lack of down-regulation of
the renin-angiotensin system due to suboptimal PTRAS
results, etc. Obviously, additional studies are required in
order to clearly illustrate the role of renal percutaneous
revascularization in BP control in patients with a SFK. In
any case, it should be noticed that although the extent of
the benefit after PTRAS in terms of hypertension treatment
cannot be accurately predicted, the probability of BP dete-
rioration is extremely low (5 out of 194 patients including
our series), making PTRAS a safe procedure. Additionally,
as it has been shown by other series and confirmed by our
study, PTRAS apart from BP decrease, results also in a
significant decline in the number of antihypertensive med-
ications used, a fact with important social and financial
implications.
Despite the promising results, this study has several
limitations. The small cohort of patients may have limited
the expected number of adverse events and potentially
increased the chance of counterfeit positive results. More-
over, it may also have limited the existence of unfavorable
anatomy not allowing the use of DEP, such as in patients
with early main renal artery bifurcation. Although such
difficulties did not occur in our study, it is undoubtful that
they will be observed with widespread use of protection
filters in renal interventions. Most importantly, the results
of this study were not compared with an identical random-
ized control group of patients undergoing renal artery
stenting without DEP.
However, our findings demonstrate the safety and fea-
sibility of DEP in the SFK and probably imply that filter
protection devices should be routinely used in this “deli-
cate” patient population where an atheroembolic event
during catheter-based manipulations could potentially lead
even to renal failure and hemodialysis, since there is no
healthy contralateral kidney to compensate for reduced
function in the ischemic kidney. Although to date there are
no established selection criteria for DEP use in renal inter-
ventions, we believe that RAS in a SFK may represent one
of the most appropriate clinical scenarios that routine use of
DEP could be recommended. Certainly, further prospec-
tive randomized clinical trials are necessary before general-
ized utilization of filters in percutaneous revascularization
of SFKs can be justified. It is of note that the impact of DEP
in renal percutaneous interventions is mirrored in the de-
sign of the Cardiovascular Outcomes with Renal Athero-
sclerotic Lesions (CORAL) study, which is a multicenter,
randomized trial aiming to compare best medical therapy vs
best medical therapy plus PTRAS; in the stent group filter
JOURNAL OF VASCULAR SURGERY
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termined by the interventionalists.43
CONCLUSION
This study evaluated renal artery primary stenting un-
der DEP in the SFK. Our results demonstrate that this
technique is feasible, safe, and effective associated with
renal function improvement or stabilization in all patients
along with a marked decline in BP in a significant portion of
cases. In contrast with previously published series reporting
PTRAS in the SFK, in our study no short-term renal
function deterioration was noticed in any of the patients
after PTRAS. This may well be attributed to the prevention
of distal atheroembolism during stenting owing mainly to
the use of DEP and implies a beneficial role of protection
devices in the “borderline group” of patients with RAS in a
SFK.
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